Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-25T13:49:29.977Z Has data issue: false hasContentIssue false
  • English
  • Français

Placebo run-in period in studies of depressive disorders

Clinical, heuristic and research implications

Published online by Cambridge University Press:  03 January 2018

Frederic M. Quitkin ,
Patrick J. McGrath ,
Jonathan W. Stewart ,
Katja Ocepek-Welikson ,
Bonnie P. Taylor ,
Edward Nunes ,
Deborah Delivannides ,
Vito Agosti ,
Steven J. Donovan  and
Donald Ross
...Show all authors
Frederic M. Quitkin
Affiliation:
Department of Therapeutics, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institution, New York, USA
Patrick J. McGrath
Affiliation:
Department of Therapeutics, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institution, New York, USA
Jonathan W. Stewart
Affiliation:
Department of Therapeutics, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institution, New York, USA
Katja Ocepek-Welikson
Affiliation:
Department of Therapeutics, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institution, New York, USA
Bonnie P. Taylor
Affiliation:
Department of Therapeutics, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institution, New York, USA
Edward Nunes
Affiliation:
Department of Therapeutics, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institution, New York, USA
Deborah Delivannides
Affiliation:
Department of Therapeutics, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institution, New York, USA
Vito Agosti
Affiliation:
Department of Therapeutics, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institution, New York, USA
Steven J. Donovan
Affiliation:
Department of Therapeutics, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institution, New York, USA
Donald Ross
Affiliation:
Department of Therapeutics, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institution, New York, USA
Eva Petkova
Affiliation:
Department of Therapeutics, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institution, New York, USA
Donald F. Klein
Affiliation:
Department of Therapeutics, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institution, New York, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

In spite of the virtually ubiquitous nature of the initial 10-day placebo run-in period (IPR) in drug trials, there is little empirical data establishing its relevance.

Method

Data from 593 subjects were examined retrospectively to determine whether or not the prognosis of subjects minimally improved during the IPR was different to those who were unimproved. The IPR period was single-blind and was followed by a six-week double-blind phase in all studies.

Results

Twenty-six per cent of the subjects were minimally improved and 74% were unimproved. Approximately 10% of the subjects who were much improved were not followed systematically. Across a range of diagnosis, severity and chronicity subjects minimally improved (versus unimproved) after IPR had a more favourable prognosis whether assigned to drug or placebo.

Conclusions

Change during IPR appears to be a meaningful predictor. Stratification should be considered in future antidepressant studies.

Type
Papers
Information
The British Journal of Psychiatry , Volume 173 , Issue 3 , September 1998 , pp. 242 - 248
Copyright
Copyright © 1998 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ainslie, J. D. Jones, M. B. & Stiefel, J. R. (1965) Practical drug evaluation method. Archives of General Psychiatry, 12, 368–373.CrossRefGoogle ScholarPubMed
Alexander, F. & French, T. M. (1946) Psychoanalytic Therapy. New York: Ronald Press.Google Scholar
American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM–III). Washington, DC: APA.Google Scholar
Alexander, F. (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–R). Washington, DC: APA.Google Scholar
Bieiski, R. J. & Friedel, R. O. (1976) Prediction of tricyclic antidepressant response. Archives of General Psychiatry, 33, 1479–1489.Google Scholar
Brown, W. A. Durnseif, B. E. & Wernicke, J. F. (1988) Placebo response in depression: a search for predictors. Psychiatry Research, 26, 259–264.Google Scholar
Derogatis, L. R. Lipman, R. S. Rickels, K. et al (1974) The Hopkins symptom checklist (HSCL): a self-report symptom inventory. Behavioral Science, 19, 1–15.Google Scholar
Fleiss, J. L. (1986) The Design and Analysis of Clinical Experiments. New York: Wiley & Sons Inc. Google Scholar
Friedman, L. M. Furberg, C. D. & Demets, K. L. (1985) Fundamentals in Clinical Trials (2nd edn). Littleton, MA: PSG Publishing.Google Scholar
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). Rockville, MD: National Institute for Mental Health.Google Scholar
Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6, 278–296.Google Scholar
Joyce, P. R. & Paykel, E. D. (1989) Predictors of drug response in depression. Archives of General Psychiatry, 46, 88–89.CrossRefGoogle ScholarPubMed
Klerman, G. L. Dimascio, A. Weissman, M. et al (1974) Treatment of depression by drugs and psychotherapy. American Journal of Psychiatry, 131, 186–191.Google Scholar
McGrath, P. J. Quitkin, F. M. Stewart, J. W. et al (1981) An open clinical trial of mianserin. American Journal of Psychiatry, 138, 530–532.Google Scholar
McGrath, P. J. Rabkin, J. G. Stewart, J. W. et al (1985) Placebo-controlled study of mianserin in depressed out-patients. Neuropsychobiotogy, 14, 128–132.Google Scholar
Quitkin, F. M. Stewart, J. W. McGrath, P. J. et al (1993) Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. British Journal of Psychiatry 163 (suppl. 21), 30–34.Google Scholar
Rabkin, J. G. (1987) Baseline characteristics of 10-day placebo washout responder in antidepressant trials. Psychiatry Research, 21, 9–22.Google Scholar
Reimherr, F. W. Ward, M. F. & Byerley, W. R. (1989) The introductory placebo washout: a retrospective evaluation. Psychiatry Research, 30, 191–199.Google Scholar
Spitzer, R. Endicott, J. & Robins, E. (1978) Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry, 35, 773–782.Google Scholar
Stassen, H. H. Angst, J. & Delini-Stula, A. (1994) Severity at baseline and onset of improvement in depression. Meta-analysis of imipramine and moclobemide versus placebo. European Psychiatry, 9, 129–136.Google Scholar
Stewart, J. W. Quitkin, F. M. Fyer, A. et al (1980) Efficacy of desipramine in endogenmorphically depressed patients. Journal of Affective Disorders, 2, 165–176.Google Scholar
Stewart, J. W. Quitkin, F. M. McGrath, P. J. et al (1981) Efficacy of desipramine in mildly depressed patients: a double-blind placebo-controlled trial. Psychopharmacology Bulletin, 17, 159–161.Google ScholarPubMed
Stewart, J. W. McGrath, P. J. Quitkin, F. M. et al (1989) Relevance of DSM–III depressive subtype and chronicity of antidepressant efficacy in atypical depression: differential response to phenelzine, imipramine and placebo. Archives of General Psychiatry, 46, 1080–1087.Google Scholar
Stewart, J. W. McGrath, P. J. Rabkin, J. G. et al (1993) Atypical depression: a valid clinical entity? Psychiatric Clinics of North America, 16, 479–495.Google Scholar
Trivedi, M. H. & Rush, J. (1994) Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology, 11, 33–42.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.